Emerging roles for RNA-binding proteins as effectors and regulators of cardiovascular disease

European Heart Journal

Volumn 38, Issue 18, 2017, Pages 1380-1388

  De Bruin, Ruben G ^a   Rabelink, Ton J ^a   Van Zonneveld, Anton Jan ^a   Van Der Veer, Eric P ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alternative splicing; Cardiovascular disease; Post transcriptional gene regulation; RNA therapeutics; RNA binding proteins

Indexed keywords

ELAV LIKE PROTEIN 1; FILAMIN; FILAMIN C GAMMA; MESSENGER RNA; MUSCLEBLIND PROTEIN; MYOSIN HEAVY CHAIN; MYOSIN HEAVY CHAIN 7; QUAKING PROTEIN; RNA BINDING PROTEIN; SERINE ARGININE RICH SPLICING FACTOR; TRANSCRIPTOME; TROPONIN I; TROPONIN T; UNCLASSIFIED DRUG; RNA;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ALTERNATIVE RNA SPLICING; AORTIC STENOSIS; CARDIAC MUSCLE CELL; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR TISSUE; CELL DEDIFFERENTIATION; CELLULAR DISTRIBUTION; CONGESTIVE CARDIOMYOPATHY; CONSENSUS SEQUENCE; EXCITATION CONTRACTION COUPLING; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEART DEVELOPMENT; HUMAN; ISCHEMIC CARDIOMYOPATHY; MACROPHAGE; MONOCYTE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RNA PROCESSING; RNA-BINDING DOMAIN; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULAR SMOOTH MUSCLE CELL; ENDOTHELIUM CELL; GENE THERAPY; GENETICS; PHYSIOLOGY; PROCEDURES; STROMA CELL; VASCULAR SMOOTH MUSCLE;

ALTERNATIVE SPLICING; CARDIOVASCULAR DISEASES; ENDOTHELIAL CELLS; GENETIC THERAPY; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, CARDIAC; PHENOTYPE; RNA; RNA-BINDING PROTEINS; STROMAL CELLS; TRANSCRIPTOME;

EID: 85019655391     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehw567     Document Type: Review

References (188)

1. Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal 2014;7:re8.
2. Ritzel RM, Patel AR, Grenier JM, Crapser J, Verma R, Jellison ER, McCullough LD. Functional differences between microglia and monocytes after ischemic stroke. J Neuroinflammation 2015;12:106.
3. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004;84:767-801.
4. Bijkerk R, de Bruin RG, van Solingen C, Duijs JM, Kobayashi K, van der Veer EP, ten Dijke P, Rabelink TJ, Goumans MJ, van Zonneveld AJ. MicroRNA-155 functions as a negative regulator of RhoA signaling in TGF-beta-induced endothelial to mesenchymal transition. Microrna 2012;1:2-10.
5. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-126.
6. Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL, Gorbatov R, Sukhova GK, Gerhardt LM, Smyth D, Zavitz CC, Shikatani EA, Parsons M, van Rooijen N, Lin HY, Husain M, Libby P, Nahrendorf M, Weissleder R, Swirski FK. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med 2013;19:1166-1172.
7. Holmes DR Jr, Taggart DP. Revascularization in stable coronary artery disease: a combined perspective from an interventional cardiologist and a cardiac surgeon. Eur Heart J 2016;37:1873-1882.
8. Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Perez-Vizcayno MJ, Byrne RA, Kastrati A, Meier B, Salanti G, Juni P, Windecker S. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet 2015;386:655-664.
9. Zargham R. Preventing restenosis after angioplasty: a multistage approach. Clin Sci 2008;114:257-264.
10. Ahuja P, Sdek P, MacLellan WR, Cardiac myocyte cell cycle control in development, disease, and regeneration 2007;87:521-544.
11. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006;86:515-581.
12. Hilgendorf I, Swirski FK, Robbins CS. Monocyte fate in atherosclerosis. Arterioscler Thromb Vasc Biol 2015;35:272-279.
13. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011;11:723-737.
14. Chistiakov DA, Bobryshev YV, Orekhov AN. Macrophage-mediated cholesterol handling in atherosclerosis. J Cell Mol Med 2016;20:17-28.
15. Beckman JA, Creager MA. The nonlipid effects of statins on endothelial function. Trends Cardiovasc Med 2006;16:156-162.
16. Parmar KM, Nambudiri V, Dai G, Larman HB, Gimbrone MA Jr, Garcia-Cardena G. Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. J Biol Chem 2005;280:26714-26719.
17. Sen-Banerjee S, Mir S, Lin Z, Hamik A, Atkins GB, Das H, Banerjee P, Kumar A, Jain MK. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation 2005;112:720-726.
18. Fish JE, Santoro MM, Morton SU, Yu S, Yeh R-F, Wythe JD, Ivey KN, Bruneau BG, Stainier DY, Srivastava D. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008;15:272-284.
19. van Solingen C, Seghers L, Bijkerk R, Duijs JM, Roeten MK, van Oeveren-Rietdijk AM, Baelde HJ, Monge M, Vos JB, de Boer HC, Quax PH, Rabelink TJ, van Zonneveld AJ. Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis. J Cell Mol Med 2009;13:1577-1585.
20. de Klerk E, T Hoen PA. Alternative mRNA transcription, processing, and translation: insights from RNA sequencing. Trends Genet 2015;31:128-139.
21. Wahlestedt C. Targeting long non-coding RNA to therapeutically upregulate gene expression. Nat Rev Drug Discov 2013;12:433-446.
22. Kafasla P, Skliris A, Kontoyiannis DL. Post-transcriptional coordination of immunological responses by RNA-binding proteins. Nat Immunol 2014;15:492-502.
23. Neelamraju Y, Hashemikhabir S, Janga SC. The human RBPome: from genes and proteins to human disease. J Proteomics 2015;127:61-70.
24. Sheng JJ, Jin JP. Gene regulation, alternative splicing, and posttranslational modification of troponin subunits in cardiac development and adaptation: a focused review. Front Physiol 2014;5:165.
25. van der Veer EP, de Bruin RG, Kraaijeveld AO, de Vries MR, Bot I, Pera T, Segers FM, Trompet S, van Gils JM, Roeten MK, Beckers CM, van Santbrink PJ, Janssen A, van Solingen C, Swildens J, de Boer HC, Peters EA, Bijkerk R, Rousch M, Doop M, Kuiper J, Schalij MJ, van der Wal AC, Richard S, van Berkel TJ, Pickering JG, Hiemstra PS, Goumans MJ, Rabelink TJ, de Vries AA, Quax PH, Jukema JW, Biessen EA, van Zonneveld AJ. Quaking, an RNA-binding protein, is a critical regulator of vascular smooth muscle cell phenotype. Circ Res 2013;113:1065-1075.
26. Beckmann BM, Horos R, Fischer B, Castello A, Eichelbaum K, Alleaume AM, Schwarzl T, Curk T, Foehr S, Huber W, Krijgsveld J, Hentze MW. The RNAbinding proteomes from yeast to man harbour conserved enigmRBPs. Nature Commun 2015;6:10127.
27. Kazan H, Ray D, Chan ET, Hughes TR, Morris Q. RNAcontext: a new method for learning the sequence and structure binding preferences of RNA-binding proteins. PLoS Comput Biol 2010;6:e1000832.
28. Ray D, Kazan H, Chan ET, Pena Castillo L, Chaudhry S, Talukder S, Blencowe BJ, Morris Q, Hughes TR. Rapid and systematic analysis of the RNA recognition specificities of RNA-binding proteins. Nat Biotechnol 2009;27:667-670.
29. Ray D, Kazan H, Cook KB, Weirauch MT, Najafabadi HS, Li X, Gueroussov S, Albu M, Zheng H, Yang A, Na H, Irimia M, Matzat LH, Dale RK, Smith SA, Yarosh CA, Kelly SM, Nabet B, Mecenas D, Li W, Laishram RS, Qiao M, Lipshitz HD, Piano F, Corbett AH, Carstens RP, Frey BJ, Anderson RA, Lynch KW, Penalva LO, Lei EP, Fraser AG, Blencowe BJ, Morris QD, Hughes TR. A compendium of RNA-binding motifs for decoding gene regulation. Nature 2013;499:172-177.
30. Galarneau A, Richard S. Target RNA motif and target mRNAs of the quaking STAR protein. Nat Struct Mol Biol 2005;12:691-698.
31. Galarneau A, Richard S. The STAR RNA binding proteins GLD-1, QKI, SAM68 and SLM-2 bind bipartite RNA motifs. BMC Mol Biol 2009;10:47.
32. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet 2014;15:541-555.
33. Aartsma-Rus A. New momentum for the field of oligonucleotide therapeutics. Mol Ther 2016;24:193-194.
34. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater 2013;12:967-977.
35. Hillier LW, Coulson A, Murray JI, Bao Z, Sulston JE, Waterston RH. Genomics in C. elegans: so many genes, such a little worm. Genome Res 2005;15:1651-1660.
36. Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature 2012;489:57-74.
37. Hube F, Francastel C. Mammalian introns: when the junk generates molecular diversity. Int J Mol Sci 2015;16:4429-4452.
38. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011;12:861-874.
39. Archer K, Broskova Z, Bayoumi AS, Teoh JP, Davila A, Tang Y, Su H, Kim IM. Long non-coding RNAs as master regulators in cardiovascular diseases. Int J Mol Sci 2015;16:23651-23667.
40. Dey BK, Mueller AC, Dutta A. Long non-coding RNAs as emerging regulators of differentiation, development, and disease. Transcription 2014;5:e944014.
41. Earls LR, Westmoreland JJ, Zakharenko SS. Non-coding RNA regulation of synaptic plasticity and memory: implications for aging. Ageing Res Rev 2014;17:34-42.
42. Haemmerle M, Gutschner T. Long non-coding RNAs in cancer and development: where do we go from here?. Int J Mol Sci 2015;16:1395-1405.
43. Smolle E, Haybaeck J. Non-coding RNAs and lipid metabolism. Int J Mol Sci 2014;15:13494-13513.
44. Thum T, Condorelli G. Long noncoding RNAs and microRNAs in cardiovascular pathophysiology. Circ Res 2015;116:751-762.
45. Boon RA, Jae N, Holdt L, Dimmeler S. Long noncoding RNAs: from clinical genetics to therapeutic Targets?. J Am Coll Cardiol 2016;67:1214-1226.
46. Elzenaar I, Pinto YM, van Oort RJ. MicroRNAs in heart failure: new targets in disease management. Clin Pharmacol Ther 2013;94:480-489.
47. Marian AJ. Recent developments in cardiovascular genetics and genomics. Circ Res 2014;115:e11-e17.
48. Elia L, Condorelli G. RNA (Epi)genetics in cardiovascular diseases. J Mol Cell Cardiol 2015;89:11-16.
49. Lunde BM, Moore C, Varani G. RNA-binding proteins: modular design for efficient function. Nat Rev Mol Cell Biol 2007;8:479-490.
50. Weyn-Vanhentenryck SM, Zhang C. mCarts: genome-wide prediction of clustered sequence motifs as binding sites for RNA-binding proteins. Methods Mol Biol 2016;1421:215-226.
51. Corcoran DL, Georgiev S, Mukherjee N, Gottwein E, Skalsky RL, Keene JD, Ohler U. PARalyzer: definition of RNA binding sites from PAR-CLIP short-read sequence data. Genome Biol 2011;12:R79.
52. Fu XD, Ares M Jr. Context-dependent control of alternative splicing by RNAbinding proteins. Nat Rev Genet 2014;15:689-701.
53. Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, Rothballer A, Ascano M Jr, Jungkamp AC, Munschauer M, Ulrich A, Wardle GS, Dewell S, Zavolan M, Tuschl T. Transcriptome-wide identification of RNAbinding protein and microRNA target sites by PAR-CLIP. Cell 2010;141:129-141.
54. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB. Alternative isoform regulation in human tissue transcriptomes. Nature 2008;456:470-476.
55. Will CL, Luhrmann R. Spliceosome structure and function. Cold Spring Harb Perspect Biol 2011;3:1-25.
56. Wahl MC, Luhrmann R. SnapShot: spliceosome dynamics I. Cell 2015;161:1474-14e1.
57. Wahl MC, Will CL, Luhrmann R. The spliceosome: design principles of a dynamic RNP machine. Cell 2009;136:701-718.
58. Hu Z, Scott HS, Qin G, Zheng G, Chu X, Xie L, Adelson DL, Oftedal BE, Venugopal P, Babic M, Hahn CN, Zhang B, Wang X, Li N, Wei C. Revealing missing human protein isoforms based on Ab Initio prediction, RNA-seq and proteomics. Sci Rep 2015;5:10940.
59. Denis MM, Tolley ND, Bunting M, Schwertz H, Jiang H, Lindemann S, Yost CC, Rubner FJ, Albertine KH, Swoboda KJ, Fratto CM, Tolley E, Kraiss LW, McIntyre TM, Zimmerman GA, Weyrich AS. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell 2005;122:379-391.
60. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008;5:621-628.
61. Anderson PA, Greig A, Mark TM, Malouf NN, Oakeley AE, Ungerleider RM, Allen PD, Kay BK. Molecular basis of human cardiac troponin T isoforms expressed in the developing, adult, and failing heart. Circ Res 1995;76:681-686.
62. Wuytack F, van den Bosch L, Ver Heyen M, Baba-Aissa F, Raeymaekers L, Casteels R. Regulation of alternative splicing of the SERCA2 pre-mRNA in muscle. Ann N Y Acad Sci 1998;853:372-375.
63. Yang TP, Agellon LB, Walsh A, Breslow JL, Tall AR. Alternative splicing of the human cholesteryl ester transfer protein gene in transgenic mice. Exon exclusion modulates gene expression in response to dietary or developmental change. J Biol Chem 1996;271:12603-12609.
64. Blech-Hermoni Y, Ladd AN. RNA binding proteins in the regulation of heart development. Int J Biochem Cell Biol 2013;45:2467-2478.
65. Bult CJ, Krupke DM, Begley DA, Richardson JE, Neuhauser SB, Sundberg JP, Eppig JT. Mouse Tumor Biology (MTB): a database of mouse models for human cancer. Nucleic Acids Res 2015;43:D818-D824.
66. Eppig JT, Blake JA, Bult CJ, Kadin JA, Richardson JE. The Mouse Genome Database (MGD): facilitating mouse as a model for human biology and disease. Nucleic Acids Res 2015;43:D726-D736.
67. Smith CM, Finger JH, Hayamizu TF, McCright IJ, Xu J, Berghout J, Campbell J, Corbani LE, Forthofer KL, Frost PJ, Miers D, Shaw DR, Stone KR, Eppig JT, Kadin JA, Richardson JE, Ringwald M. The mouse Gene Expression Database (GXD): 2014 update. Nucleic Acids Res 2014;42:D818-D824.
68. Verma SK, Deshmukh V, Liu P, Nutter CA, Espejo R, Hung ML, Wang GS, Yeo GW, Kuyumcu-Martinez MN. Reactivation of fetal splicing programs in diabetic hearts is mediated by protein kinase C signaling. J Biol Chem 2013;288:35372-35386.
69. Giudice J, Xia Z, Wang ET, Scavuzzo MA, Ward AJ, Kalsotra A, Wang W, Wehrens XH, Burge CB, Li W, Cooper TA. Alternative splicing regulates vesicular trafficking genes in cardiomyocytes during postnatal heart development. Nat Commun 2014;5:3603.
70. Kalsotra A, Xiao X, Ward AJ, Castle JC, Johnson JM, Burge CB, Cooper TA. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci U S A 2008;105:20333-20338.
71. Olson EN. Gene regulatory networks in the evolution and development of the heart. Science 2006;313:1922-1927.
72. Kong SW, Hu YW, Ho JW, Ikeda S, Polster S, John R, Hall JL, Bisping E, Pieske B, dos Remedios CG, Pu WT. Heart failure-associated changes in RNA splicing of sarcomere genes. Circ Cardiovasc Genet 2010;3:138-146.
73. Xu X, Yang D, Ding JH, Wang W, Chu PH, Dalton ND, Wang HY, Bermingham JR, Jr., Ye Z, Liu F, Rosenfeld MG, Manley JL, Ross J Jr, Chen J, Xiao RP, Cheng H, Fu XD. ASF/SF2-regulated CaMKIIdelta alternative splicing temporally reprograms excitation-contraction coupling in cardiac muscle. Cell 2005;120:59-72.
74. Brauch KM, Karst ML, Herron KJ, de Andrade M, Pellikka PA, Rodeheffer RJ, Michels VV, Olson TM. Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy. J Am Coll Cardiol 2009;54:930-941.
75. Li D, Morales A, Gonzalez-Quintana J, Norton N, Siegfried JD, Hofmeyer M, Hershberger RE. Identification of novel mutations in RBM20 in patients with dilated cardiomyopathy. Clin Transl Sci 2010;3:90-97.
76. Maatz H, Jens M, Liss M, Schafer S, Heinig M, Kirchner M, Adami E, Rintisch C, Dauksaite V, Radke MH, Selbach M, Barton PJ, Cook SA, Rajewsky N, Gotthardt M, Landthaler M, Hubner N. RNA-binding protein RBM20 represses splicing to orchestrate cardiac pre-mRNA processing. J Clin Invest 2014;124:3419-3430.
77. Guo W, Schafer S, Greaser ML, Radke MH, Liss M, Govindarajan T, Maatz H, Schulz H, Li S, Parrish AM, Dauksaite V, Vakeel P, Klaassen S, Gerull B, Thierfelder L, Regitz-Zagrosek V, Hacker TA, Saupe KW, Dec GW, Ellinor PT, MacRae CA, Spallek B, Fischer R, Perrot A, Ozcelik C, Saar K, Hubner N, Gotthardt M. RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing. Nat Med 2012;18:766-773.
78. Wang GS, Kearney DL, De Biasi M, Taffet G, Cooper TA. Elevation of RNAbinding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy. J Clin Invest 2007;117:2802-2811.
79. Freyermuth F, Rau F, Kokunai Y, Linke T, Sellier C, Nakamori M, Kino Y, Arandel L, Jollet A, Thibault C, Philipps M, Vicaire S, Jost B, Udd B, Day JW, Duboc D, Wahbi K, Matsumura T, Fujimura H, Mochizuki H, Deryckere F, Kimura T, Nukina N, Ishiura S, Lacroix V, Campan-Fournier A, Navratil V, Chautard E, Auboeuf D, Horie M, Imoto K, Lee KY, Swanson MS, Lopez de Munain A, Inada S, Itoh H, Nakazawa K, Ashihara T, Wang E, Zimmer T, Furling D, Takahashi MP, Charlet-Berguerand N. Splicing misregulation of SCN5A contributes to cardiac-conduction delay and heart arrhythmia in myotonic dystrophy. Nat Commun 2016;7:11067.
80. Zhou A, Greener I, Xie A, Shi G, Yang K-C, Liu H, Rutledge C, Dudley S. mRNA stability hu proteins regulate human cardiac sodium channel expression. Circulation 2014;130:A15892-A15892.
81. Zhang Y, Si Y, Ma N, Mei J. The RNA-binding protein PCBP2 inhibits Ang IIinduced hypertrophy of cardiomyocytes though promoting GPR56 mRNA degeneration. Biochem Biophys Res Commun 2015;464:679-684.
82. Li J, Xie D, Huang J, Lv F, Shi D, Liu Y, Lin L, Geng L, Wu Y, Liang D. Cold-inducible RNA-binding protein regulates cardiac repolarization by targeting transient outward potassium channels. Circ Res 2015;116:1655-1659.
83. Agema W, Jukema J, Pimstone S, Kastelein J. Genetic aspects of restenosis after percutaneous coronary interventions; towards more tailored therapy. Eur Heart J 2001;22:2058-2074.
84. Lee T, Safdar N, Mistry MJ, Wang Y, Chauhan V, Campos B, Munda R, Cornea V, Roy-Chaudhury P. Preexisting venous calcification prior to dialysis vascular access surgery. Semin Dial 2012;25:592-595.
85. Mitchell RN, Libby P. Vascular remodeling in transplant vasculopathy. Circ Res 2007;100:967-978.
86. Nagai R, Kuro-O M, Babij P, Periasamy M. Identification of two types of smooth muscle myosin heavy chain isoforms by cDNA cloning and immunoblot analysis. J Biol Chem 1989;264:9734-9737.
87. Lenz S, Lohse P, Seidel U, Arnold H. The alkali light chains of human smooth and nonmuscle myosins are encoded by a single gene. Tissue-specific expression by alternative splicing pathways. J Biol Chem 1989;264:9009-9015.
88. Nabeshima Y, Nonomura Y, Fujii-Kuriyama Y. Nonmuscle and smooth muscle myosin light chain mRNAs are generated from a single gene by the tissuespecific alternative RNA splicing. J Biol Chem 1987;262:10608-10612.
89. van Eys GJ, Völler MC, Timmer ED, Wehrens XH, Small JV, Schalken JA, Ramaekers FC, van der Loop FT. Smoothelin expression characteristics: development of a smooth muscle cell in vitro system and identification of a vascular variant. Cell Struct Funct 1997;22:65-72.
90. Rensen S, Thijssen V, De Vries C, Doevendans P, Detera-Wadleigh S, Van Eys G. Expression of the smoothelin gene is mediated by alternative promoters. Cardiovasc Res 2002;55:850-863.
91. Ruiz-Opazo N, Nadal-Ginard B. Alpha-tropomyosin gene organization. Alternative splicing of duplicated isotype-specific exons accounts for the production of smooth and striated muscle isoforms. J Biol Chem 1987;262:4755-4765.
92. Wieczorek DF, Smith C, Nadal-Ginard B. The rat alpha-tropomyosin gene generates a minimum of six different mRNAs coding for striated, smooth, and nonmuscle isoforms by alternative splicing. Mol Cell Biol 1988;8:679-694.
93. Byrne B, Kaczorowski Y, Coutu M, Craig S. Chicken vinculin and meta-vinculin are derived from a single gene by alternative splicing of a 207-base pair exon unique to meta-vinculin. J Biol Chem 1992;267:12845-12850.
94. Strasser P, Gimona M, Moessler H, Herzog M, Small JV. Mammalian calponin. FEBS Lett 1993;330:13-18.
95. Humphrey MB, Herrera-Sosa H, Gonzalez G, Lee R, Bryan J. Cloning of cDNAs encoding human caldesmons. Gene 1992;112:197-204.
96. Sobue K, Sellers J. Caldesmon, a novel regulatory protein in smooth muscle and nonmuscle actomyosin systems. J Biol Chem 1991;266:12115-12118.
97. Justice MJ, Bode VC. Three ENU-induced alleles of the murine quaking locus are recessive embryonic lethal mutations. Genet Res 1988;51:95-102.
98. Li Z, Takakura N, Oike Y, Imanaka T, Araki K, Suda T, Kaname T, Kondo T, Abe K, Yamamura K. Defective smooth muscle development in qkI-deficient mice. Dev Growth Differ 2003;45:449-462.
99. Noveroske JK, Lai L, Gaussin V, Northrop JL, Nakamura H, Hirschi KK, Justice MJ. Quaking is essential for blood vessel development. Genesis 2002;32:218-230.
100. Creemers EE, Sutherland LB, Oh J, Barbosa AC, Olson EN. Coactivation of MEF2 by the SAP domain proteins myocardin and MASTR. Molecular Cell 2006;23:83-96.
101. Ilagan RM, Genheimer CW, Quinlan SF, Guthrie KI, Sangha N, Ramachandrannair S, Kelley RW, Presnell SC, Basu J, Ludlow JW. Smooth muscle phenotypic diversity is mediated through alterations in myocardin gene splicing. J Cell Physiol 2011;226:2702-2711.
102. Miano JM. Myocardin in biology and disease. J Biomed Res 2015;29:3-19.
103. Pullmann R Jr, Juhaszova M, Lopez de Silanes I, Kawai T, Mazan-Mamczarz K, Halushka MK, Gorospe M. Enhanced proliferation of cultured human vascular smooth muscle cells linked to increased function of RNA-binding protein HuR. J Biol Chem 2005;280:22819-22826.
104. Misquitta CM, Chen T, Grover AK. Control of protein expression through mRNA stability in calcium signalling. Cell Calcium 2006;40:329-346.
105. Nickenig G, Michaelsen F, Muller C, Berger A, Vogel T, Sachinidis A, Vetter H, Bohm M. Destabilization of AT(1) receptor mRNA by calreticulin. Circ Res 2002;90:53-58.
106. Pende A, Contini L, Sallo R, Passalacqua M, Tanveer R, Port JD, Lotti G. Characterization of RNA-binding proteins possibly involved in modulating human AT 1 receptor mRNA stability. Cell Biochem Funct 2008;26:493-501.
107. Paukku K, Backlund M, De Boer RA, Kalkkinen N, Kontula KK, Lehtonen JY. Regulation of AT1R expression through HuR by insulin. Nucleic Acids Res 2012;40:5250-5261.
108. Claggett B, Packer M, McMurray JJ, Swedberg K, Rouleau J, Zile MR, Jhund P, Lefkowitz M, Shi V, Solomon SD. Estimating the long-term treatment benefits of Sacubitril-Valsartan. N Engl J Med 2015;373:2289-2290.
109. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007;369:1208-1219.
110. Kramann R, Schneider RK, DiRocco DP, Machado F, Fleig S, Bondzie PA, Henderson JM, Ebert BL, Humphreys BD. Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell 2015;16:51-66.
111. Pu KM, Sava P, Gonzalez AL. Microvascular targets for anti-fibrotic therapeutics. Yale J Biol Med 2013;86:537-554.
112. Howard CM, Baudino TA. Dynamic cell-cell and cell-ECM interactions in the heart. J Mol Cell Cardiol 2014;70:19-26.
113. Amadio M, Scapagnini G, Lupo G, Drago F, Govoni S, Pascale A. PKCbetaII/ HuR/VEGF: a new molecular cascade in retinal pericytes for the regulation of VEGF gene expression. Pharmacol Res 2008;57:60-66.
114. Davis J, Salomonis N, Ghearing N, Lin SC, Kwong JQ, Mohan A, Swanson MS, Molkentin JD. MBNL1-mediated regulation of differentiation RNAs promotes myofibroblast transformation and the fibrotic response. Nat Commun 2015;6:10084.
115. Felkin LE, Narita T, Germack R, Shintani Y, Takahashi K, Sarathchandra P, Lopez-Olaneta MM, Gomez-Salinero JM, Suzuki K, Barton PJ, Rosenthal N, Lara-Pezzi E. Calcineurin splicing variant calcineurin Abeta1 improves cardiac function after myocardial infarction without inducing hypertrophy. Circulation 2011;123:2838-2847.
116. Ganz P, Hsue PY. Endothelial dysfunction in coronary heart disease is more than a systemic process. Eur Heart J 2013;34:2025-2027.
117. Huveneers S, Daemen MJ, Hordijk PL. Between Rho(k) and a hard place: the relation between vessel wall stiffness, endothelial contractility, and cardiovascular disease. Circ Res 2015;116:895-908.
118. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-456.
119. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, Shin WS, Liao JK. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60-68.
120. Alexander LM, Kutz JL, Kenney WL. Tetrahydrobiopterin increases NOdependent vasodilation in hypercholesterolemic human skin through eNOScoupling mechanisms. Am J Physiol Regul Integr Comp Physiol 2013;304:R164-R169.
121. Dekker RJ, Boon RA, Rondaij MG, Kragt A, Volger OL, Elderkamp YW, Meijers JC, Voorberg J, Pannekoek H, Horrevoets AJ. KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium. Blood 2006;107:4354-4363.
122. Dekker RJ, van Soest S, Fontijn RD, Salamanca S, de Groot PG, VanBavel E, Pannekoek H, Horrevoets AJ. Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Kruppel-like factor (KLF2). Blood 2002;100:1689-1698.
123. Gimbrone MA Jr, Nagel T, Topper JN. Biomechanical activation: an emerging paradigm in endothelial adhesion biology. J Clin Invest 1997;99:1809-1813.
124. SenBanerjee S, Lin Z, Atkins GB, Greif DM, Rao RM, Kumar A, Feinberg MW, Chen Z, Simon DI, Luscinskas FW, Michel TM, Gimbrone MA Jr, Garcia-Cardena G, Jain MK. KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med 2004;199:1305-1315.
125. de Bruin RG, van der Veer EP, Prins J, Lee DH, Dane MJ, Zhang H, Roeten MK, Bijkerk R, de Boer HC, Rabelink TJ. The RNA-binding protein quaking maintains endothelial barrier function and affects VE-cadherin and b-catenin protein expression. Sci Rep 2016;6.
126. Rhee WJ, Ni CW, Zheng Z, Chang K, Jo H, Bao G. HuR regulates the expression of stress-sensitive genes and mediates inflammatory response in human umbilical vein endothelial cells. Proc Natl Acad Sci U S A 2010;107:6858-6863.
127. Hui J, Stangl K, Lane WS, Bindereif A. HnRNP L stimulates splicing of the eNOS gene by binding to variable-length CA repeats. Nat Struct Biol 2003;10:33-37.
128. Lorenz M, Hewing B, Hui J, Zepp A, Baumann G, Bindereif A, Stangl V, Stangl K. Alternative splicing in intron 13 of the human eNOS gene: a potential mechanism for regulating eNOS activity. FASEB J 2007;21:1556-1564.
129. Osera C, Martindale JL, Amadio M, Kim J, Yang X, Moad CA, Indig FE, Govoni S, Abdelmohsen K, Gorospe M, Pascale A. Induction of VEGFA mRNA translation by CoCl2 mediated by HuR. RNA Biol 2015;12:1121-1130.
130. Vumbaca F, Phoenix KN, Rodriguez-Pinto D, Han DK, Claffey KP. Doublestranded RNA-binding protein regulates vascular endothelial growth factor mRNA stability, translation, and breast cancer angiogenesis. Mol Cell Biol 2008;28:772-783.
131. Blanco FJ, Bernabeu C. Alternative splicing factor or splicing factor-2 plays a key role in intron retention of the endoglin gene during endothelial senescence. Aging Cell 2011;10:896-907.
132. Galban S, Kuwano Y, Pullmann R Jr, Martindale JL, Kim HH, Lal A, Abdelmohsen K, Yang X, Dang Y, Liu JO, Lewis SM, Holcik M, Gorospe M. RNA-binding proteins HuR and PTB promote the translation of hypoxiainducible factor 1alpha. Mol Cell Biol 2008;28:93-107.
133. de Brot S, Ntekim A, Cardenas R, James V, Allegrucci C, Heery DM, Bates DO, Odum N, Persson JL, Mongan NP. Regulation of vascular endothelial growth factor in prostate cancer. Endocr Relat Cancer 2015;22:R107-R123.
134. Mamlouk S, Wielockx B. Hypoxia-inducible factors as key regulators of tumor inflammation. Int J Cancer 2013;132:2721-2729.
135. Seon BK, Haba A, Matsuno F, Takahashi N, Tsujie M, She X, Harada N, Uneda S, Tsujie T, Toi H, Tsai H, Haruta Y. Endoglin-targeted cancer therapy. Curr Drug Deliv 2011;8:135-143.
136. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010;327:656-661.
137. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu Y-J, MacPherson G, Randolph GJ. Nomenclature of monocytes and dendritic cells in blood. Blood 2010;116:e74-e80.
138. Anderson P. Post-transcriptional control of cytokine production. Nat Immunol 2008;9:353-359.
139. Chen C-Y, Gherzi R, Ong S-E, Chan EL, Raijmakers R, Pruijn GJ, Stoecklin G, Moroni C, Mann M, Karin M. AU binding proteins recruit the exosome to degrade ARE-containing mRNAs. Cell 2001;107:451-464.
140. Shaw G, Kamen R. A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986;46:659-667.
141. Leppek K, Schott J, Reitter S, Poetz F, Hammond MC, Stoecklin G. Roquin promotes constitutive mRNA decay via a conserved class of stem-loop recognition motifs. Cell 2013;153:869-881.
142. Sakurai S, Ohto U, Shimizu T. Structure of human Roquin-2 and its complex with constitutive-decay element RNA. Acta Crystallogr F Struct Biol Commun 2015;71:1048-1054.
143. Libby P, Hansson GK. Inflammation and immunity in diseases of the arterial tree: players and layers. Circ Res 2015;116:307-311.
144. Dehghan A, Bis JC, White CC, Smith AV, Morrison AC, Cupples LA, Trompet S, Chasman DI, Lumley T, Völker U. Genome-wide association study for incident myocardial infarction and coronary heart disease in prospective cohort studies: the CHARGE consortium. PloS One 2016;11:e0144997.
145. de Bruin RG, Shiue L, Prins J, de Boer HC, Singh A, Fagg WS, van Gils JM, Duijs JM, Katzman S, Kraaijeveld AO, Bohringer S, Leung WY, Kielbasa SM, Donahue JP, van der Zande PH, Sijbom R, van Alem CM, Bot I, van Kooten C, Jukema JW, Van Esch H, Rabelink TJ, Kazan H, Biessen EA, Ares M Jr, van Zonneveld AJ, van der Veer EP. Quaking promotes monocyte differentiation into pro-atherogenic macrophages by controlling pre-mRNA splicing and gene expression. Nat Commun 2016;7:10846.
146. Hammoudi N, Ishikawa K, Hajjar RJ. Adeno-associated virus-mediated gene therapy in cardiovascular disease. Curr Opin Cardiol 2015;30:228-234.
147. Hinkel R, Trenkwalder T, Kupatt C. Gene therapy for ischemic heart disease. Expert Opin Biol Ther 2011;11:723-737.
148. Hinkel R, Lange P, Petersen B, Gottlieb E, Ng JK, Finger S, Horstkotte J, Lee S, Thormann M, Knorr M, El-Aouni C, Boekstegers P, Reichart B, Wenzel P, Niemann H, Kupatt C. Heme oxygenase-1 gene therapy provides cardioprotection via control of post-ischemic inflammation: an experimental study in a preclinical pig model. J Am Coll Cardiol 2015;66:154-165.
149. Woitek F, Zentilin L, Hoffman NE, Powers JC, Ottiger I, Parikh S, Kulczycki AM, Hurst M, Ring N, Wang T, Shaikh F, Gross P, Singh H, Kolpakov MA, Linke A, Houser SR, Rizzo V, Sabri A, Madesh M, Giacca M, Recchia FA. Intracoronary cytoprotective gene therapy: a study of VEGF-B167 in a pre-clinical animal model of dilated cardiomyopathy. J Am Coll Cardiol 2015;66:139-153.
150. Yla-Herttuala S. Gene therapy for heart failure: back to the bench. Mol Ther 2015;23:1551-1552.
151. Gao G, Dudley SC Jr. SCN5A splicing variants and the possibility of predicting heart failure-associated arrhythmia. Expert Rev Cardiovasc Ther 2013;11:117-119.
152. van den Hoogenhof MM, Pinto YM, Creemers EE. RNA Splicing: Regulation and Dysregulation in the Heart. Circ Res 2016;118:454-468.
153. Lin J, Hu Y, Nunez S, Foulkes AS, Cieply B, Xue C, Gerelus M, Li W, Zhang H, Rader DJ., Musunuru K, Li M, Reilly MP. Transcriptome-wide analysis reveals modulation of human macrophage inflammatory phenotype through alternative splicing. Arterioscler Thromb Vasc Biol 2016;36:1434-1437.
154. Tejedor JR, Tilgner H, Iannone C, Guigó R, Valcárcel J. Role of six single nucleotide polymorphisms, risk factors in coronary disease, in OLR1 alternative splicing. RNA 2015;21:1187-1202.
155. Aartsma-Rus A. Overview on AON design. Methods Mol Biol 2012;867:117-129.
156. Siva K, Covello G, Denti MA. Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases. Nucleic Acid Therapeutics 2014;24:69-86.
157. Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg HP, Seidman JG, Seidman CE. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994;77:701-712.
158. Azimi-Nezhad M. Vascular endothelial growth factor from embryonic status to cardiovascular pathology. Rep Biochem Mol Biol 2014;2:59-69.
159. Gramlich M, Pane LS, Zhou Q, Chen Z, Murgia M, Schotterl S, Goedel A, Metzger K, Brade T, Parrotta E, Schaller M, Gerull B, Thierfelder L, Aartsma-Rus A, Labeit S, Atherton JJ, McGaughran J, Harvey RP, Sinnecker D, Mann M, Laugwitz KL, Gawaz MP, Moretti A. Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy. EMBO Mol Med 2015;7:562-576.
160. Thygesen SJ, Sester DP, Cridland SO, Wilton SD, Stacey KJ. Correcting the NLRP3 inflammasome deficiency in macrophages from autoimmune NZB mice with exon skipping antisense oligonucleotides. Immunol Cell Biol 2016;94:520-524.
161. Bosse Y, Maghni K, Hudson TJ. 1alpha, 25-dihydroxy-vitamin D3 stimulation of bronchial smooth muscle cells induces autocrine, contractility, and remodeling processes. Physiol Genomics 2007;29:161-168.
162. Rao DA, Eid RE, Qin L, Yi T, Kirkiles-Smith NC, Tellides G, Pober JS. Interleukin (IL)-1 promotes allogeneic T cell intimal infiltration and IL-17 production in a model of human artery rejection. J Exp Med 2008;205:3145-3158.
163. Kaneda R, Takada S, Yamashita Y, Choi YL, Nonaka-Sarukawa M, Soda M, Misawa Y, Isomura T, Shimada K, Mano H. Genome-wide histone methylation profile for heart failure. Genes Cells 2009;14:69-77.
164. Schmolke M, Viemann D, Roth J, Ludwig S. Essential impact of NF-kappaB signaling on the H5N1 influenza A virus-induced transcriptome. J Immunol 2009;183:5180-5189.
165. Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jadersten M, Killick S, Verma A, Norbury CJ, Hellstrom-Lindberg E, Wainscoat JS, Boultwood J. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 2010;24:756-764.
166. Ancuta P, Liu KY, Misra V, Wacleche VS, Gosselin A, Zhou X, Gabuzda D. Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16- monocyte subsets. BMC Genomics 2009;10:403.
167. Smith JA, Barnes MD, Hong D, DeLay ML, Inman RD, Colbert RA. Gene expression analysis of macrophages derived from ankylosing spondylitis patients reveals interferon-gamma dysregulation. Arthritis Rheum 2008;58:1640-1649.
168. Raghavachari N, Xu X, Harris A, Villagra J, Logun C, Barb J, Solomon MA, Suffredini AF, Danner RL, Kato G, Munson PJ, Morris SM Jr, Gladwin MT. Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease. Circulation 2007;115:1551-1562.
169. Hou SC, Chan LW, Chou YC, Su CY, Chen X, Shih YL, Tsai PC, Shen CK, Yan YT. Ankrd17, an ubiquitously expressed ankyrin factor, is essential for the vascular integrity during embryogenesis. FEBS Lett 2009;583:2765-2771.
170. HogenEsch H, Gijbels MJ, Offerman E, van Hooft J, van Bekkum DW, Zurcher C. A spontaneous mutation characterized by chronic proliferative dermatitis in C57BL mice. Am J Pathol 1993;143:972-982.
171. Bollmann F, Wu Z, Oelze M, Siuda D, Xia N, Henke J, Daiber A, Li H, Stumpo DJ, Blackshear PJ, Kleinert H, Pautz A. Endothelial dysfunction in tristetraprolindeficient mice is not caused by enhanced tumor necrosis factor-alpha expression. J Biol Chem 2014;289:15653-15665.
172. Phillips K, Kedersha N, Shen L, Blackshear PJ, Anderson P. Arthritis suppressor genes TIA-1 and TTP dampen the expression of tumor necrosis factor alpha, cyclooxygenase 2, and inflammatory arthritis. Proc Natl Acad Sci U S A 2004;101:2011-2016.
173. Stumpo DJ, Broxmeyer HE, Ward T, Cooper S, Hangoc G, Chung YJ, Shelley WC, Richfield EK, Ray MK, Yoder MC, Aplan PD, Blackshear PJ. Targeted disruption of Zfp36l2, encoding a CCCH tandem zinc finger RNA-binding protein, results in defective hematopoiesis. Blood 2009;114:2401-2410.
174. Zekri L, Chebli K, Tourriere H, Nielsen FC, Hansen TV, Rami A, Tazi J. Control of fetal growth and neonatal survival by the RasGAP-associated endoribonuclease G3BP. Mol Cell Biol 2005;25:8703-8716.
175. Lu JY, Sadri N, Schneider RJ. Endotoxic shock in AUF1 knockout mice mediated by failure to degrade proinflammatory cytokine mRNAs. Genes Dev 2006;20:3174-3184.
176. Sakakibara S, Nakamura Y, Yoshida T, Shibata S, Koike M, Takano H, Ueda S, Uchiyama Y, Noda T, Okano H. RNA-binding protein Musashi family: roles for CNS stem cells and a subpopulation of ependymal cells revealed by targeted disruption and antisense ablation. Proc Natl Acad Sci U S A 2002;99:15194-15199.
177. Katsanou V, Milatos S, Yiakouvaki A, Sgantzis N, Kotsoni A, Alexiou M, Harokopos V, Aidinis V, Hemberger M, Kontoyiannis DL. The RNA-binding protein Elavl1/HuR is essential for placental branching morphogenesis and embryonic development. Mol Cell Biol 2009;29:2762-2776.
178. Zhang J, Modi Y, Yarovinsky T, Yu J, Collinge M, Kyriakides T, Zhu Y, Sessa WC, Pardi R, Bender JR. Macrophage beta2 integrin-mediated, HuR-dependent stabilization of angiogenic factor-encoding mRNAs in inflammatory angiogenesis. Am J Pathol 2012;180:1751-1760.
179. Mende Y, Jakubik M, Riessland M, Schoenen F, Rossbach K, Kleinridders A, Kohler C, Buch T, Wirth B. Deficiency of the splicing factor Sfrs10 results in early embryonic lethality in mice and has no impact on full-length SMN/Smn splicing. Human Mol Genet 2010;19:2154-2167.
180. Langenickel TH, Olive M, Boehm M, San H, Crook MF, Nabel EG. KIS protects against adverse vascular remodeling by opposing stathmin-mediated VSMC migration in mice. J Clin Invest 2008;118:3848-3859.
181. Koscielny G, Yaikhom G, Iyer V, Meehan TF, Morgan H, Atienza-Herrero J, Blake A, Chen CK, Easty R, Di Fenza A, Fiegel T, Grifiths M, Horne A, Karp NA, Kurbatova N, Mason JC, Matthews P, Oakley DJ, Qazi A, Regnart J, Retha A, Santos LA, Sneddon DJ, Warren J, Westerberg H, Wilson RJ, Melvin DG, Smedley D, Brown SD, Flicek P, Skarnes WC, Mallon AM, Parkinson H. The International mouse phenotyping consortium web portal, a unified point of access for knockout mice and related phenotyping data. Nucleic Acids Res 2014;42:D802-D809.
182. Arany Z, Novikov M, Chin S, Ma Y, Rosenzweig A, Spiegelman BM. Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha. Proc Natl Acad Sci U S A 2006;103:10086-10091.
183. Lai L, Leone TC, Zechner C, Schaeffer PJ, Kelly SM, Flanagan DP, Medeiros DM, Kovacs A, Kelly DP. Transcriptional coactivators PGC-1alpha and PGC-lbeta control overlapping programs required for perinatal maturation of the heart. Genes Dev 2008;22:1948-1961.
184. Sanna B, Brandt EB, Kaiser RA, Pfluger P, Witt SA, Kimball TR, van Rooij E, De Windt LJ, Rothenberg ME, Tschop MH, Benoit SC, Molkentin JD. Modulatory calcineurin-interacting proteins 1 and 2 function as calcineurin facilitators in vivo. Proc Natl Acad Sci U S A 2006;103:7327-7332.
185. Ding JH, Xu X, Yang D, Chu PH, Dalton ND, Ye Z, Yeakley JM, Cheng H, Xiao RP, Ross J, Chen J, Fu XD. Dilated cardiomyopathy caused by tissue-specific ablation of SC35 in the heart. Embo J 2004;23:885-896.
186. Lelliott CJ, Medina-Gomez G, Petrovic N, Kis A, Feldmann HM, Bjursell M, Parker N, Curtis K, Campbell M, Hu P, Zhang D, Litwin SE, Zaha VG, Fountain KT, Boudina S, Jimenez-Linan M, Blount M, Lopez M, Meirhaeghe A, Bohlooly YM, Storlien L, Stromstedt M, Snaith M, Oresic M, Abel ED, Cannon B, Vidal-Puig A. Ablation of PGC-1beta results in defective mitochondrial activity, thermogenesis, hepatic function, and cardiac performance. PLoS Biol 2006;4:e369.
187. Yu YE, Morishima M, Pao A, Wang DY, Wen XY, Baldini A, Bradley A. A deficiency in the region homologous to human 17q21.33-q23.2 causes heart defects in mice. Genetics 2006;173:297-307.
188. Kuroda K, Han H, Tani S, Tanigaki K, Tun T, Furukawa T, Taniguchi Y, Kurooka H, Hamada Y, Toyokuni S, Honjo T. Regulation of marginal zone B cell development by MINT, a suppressor of Notch/RBP-J signaling pathway. Immunity 2003;18:301-312.